2004
Preferential 5-HT1A Autoreceptor Occupancy by Pindolol is Attenuated in Depressed Patients: Effect of Treatment or an Endophenotype of Depression?
Rabiner E, Bhagwagar Z, Gunn R, Cowen P, Grasby P. Preferential 5-HT1A Autoreceptor Occupancy by Pindolol is Attenuated in Depressed Patients: Effect of Treatment or an Endophenotype of Depression? Neuropsychopharmacology 2004, 29: 1688-1698. PMID: 15127080, DOI: 10.1038/sj.npp.1300472.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAdultAutoreceptorsDepressive DisorderDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedPhenotypePindololPiperazinesPsychiatric Status Rating ScalesPyridinesRadiopharmaceuticalsReceptor, Serotonin, 5-HT1ASerotonin AntagonistsTomography, Emission-ComputedIncreased Brain GABA Concentrations Following Acute Administration of a Selective Serotonin Reuptake Inhibitor
Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, Matthews P, Cowen P. Increased Brain GABA Concentrations Following Acute Administration of a Selective Serotonin Reuptake Inhibitor. American Journal Of Psychiatry 2004, 161: 368-370. PMID: 14754790, DOI: 10.1176/appi.ajp.161.2.368.Peer-Reviewed Original ResearchConceptsGamma-aminobutyric acidBrain GABA concentrationsAcute administrationGABA concentrationSelective serotonin reuptake inhibitor citalopramSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitor citalopramCortical gamma-aminobutyric acidActions of SSRIsGABA/creatine ratiosReuptake inhibitor citalopramSerotonin reuptake inhibitorsGABA neuronsSSRI treatmentReuptake inhibitorsIntravenous citalopramDepressed patientsCreatine ratioHealthy volunteersCortical levelOccipital cortexCrossover designMean increaseMagnetic resonance spectroscopyMood improvement
2003
Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients.
Sharpley A, Bhagwagar Z, Hafizi S, Whale W, Gijsman H, Cowen P. Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. The Journal Of Clinical Psychiatry 2003, 64: 192-6. PMID: 12633128, DOI: 10.4088/jcp.v64n0212.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAntidepressive AgentsAntipsychotic AgentsCross-Over StudiesDepressive DisorderDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMiddle AgedPersonality InventoryPlacebosPolysomnographyPsychiatric Status Rating ScalesRisperidoneSleep, REMTreatment OutcomeWakefulnessConceptsRapid eye movement (REM) sleepEye movement sleepDepressed patientsHealthy volunteersRisperidone treatmentMovement sleepREM sleepMedication-resistant depressed patientsTreatment-resistant depressed patientsConventional antidepressant medicationAntidepressant-like effectsAntipsychotic agent risperidoneDepression Rating ScaleMajor depressive disorderDSM-IV criteriaPatients meritRisperidone additionRisperidone augmentationAntidepressant medicationRisperidone administrationSingle doseTherapeutic dosesAugmentation agentsDepressive disorderHealthy subjects
2002
Acute citalopram administration produces correlated increases in plasma and salivary cortisol
Bhagwagar Z, Hafizi S, Cowen P. Acute citalopram administration produces correlated increases in plasma and salivary cortisol. Psychopharmacology 2002, 163: 118-120. PMID: 12185409, DOI: 10.1007/s00213-002-1149-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultArea Under CurveCitalopramCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansHydrocortisoneMaleMiddle AgedSalivaSelective Serotonin Reuptake InhibitorsConceptsSalivary cortisol levelsCortisol levelsSelective serotonin re-uptake inhibitorsSalivary cortisolSerotonin re-uptake inhibitorsAcute citalopram administrationRe-uptake inhibitorsCross-over designSalivary cortisol concentrationsCitalopram administrationIntravenous administrationCortisol releaseHealthy volunteersCortisol concentrationsSaliva cortisolCitalopramCortisolParallel increaseAdministrationCorrelated increaseAcceptable means
2001
Pindolol Augmentation of Selective Serotonin Reuptake Inhibitors: PET Evidence That the Dose Used in Clinical Trials Is Too Low
Rabiner E, Bhagwagar Z, Gunn R, Sargent P, Bench C, Cowen P, Grasby P. Pindolol Augmentation of Selective Serotonin Reuptake Inhibitors: PET Evidence That the Dose Used in Clinical Trials Is Too Low. American Journal Of Psychiatry 2001, 158: 2080-2082. PMID: 11729033, DOI: 10.1176/appi.ajp.158.12.2080.Peer-Reviewed Original ResearchMeSH KeywordsAdultBrainDepressive Disorder, MajorDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansMaleMiddle AgedPindololReceptors, SerotoninReceptors, Serotonin, 5-HT1Selective Serotonin Reuptake InhibitorsTomography, Emission-ComputedTreatment OutcomeConceptsPositron emission tomographyDose of pindololClinical trialsDepressed patientsSelective serotonin reuptake inhibitorsSignificant occupancyPresent clinical trialSerotonin reuptake inhibitorsPindolol augmentationAntidepressant medicationReuptake inhibitorsPET evidenceEmission tomographyPindololTrialsDoseAutoreceptorsMedicationsPatientsInconsistent resultsEfficacyVast majorityDosesPET measurement of the influence of corticosteroids on serotonin-1A receptor number
Montgomery A, Bench C, Young A, Hammers A, Gunn R, Bhagwagar Z, Grasby P. PET measurement of the influence of corticosteroids on serotonin-1A receptor number. Biological Psychiatry 2001, 50: 668-676. PMID: 11704073, DOI: 10.1016/s0006-3223(01)01205-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Inflammatory AgentsBinding, CompetitiveDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleHippocampusHumansHydrocortisoneHypothalamo-Hypophyseal SystemMaleMiddle AgedPituitary-Adrenal SystemReceptors, SerotoninReceptors, Serotonin, 5-HT1Tomography, Emission-ComputedConceptsPositron emission tomographyReceptor numberReceptor bindingPlacebo-controlled designInfluence of corticosteroidsSingle doseSerotonergic systemPreclinical studiesCorticosteroidsNormal subjectsModulatory effectsAlters 5Corticosteroid levelsBrain regionsEmission tomographyElevated levelsPET measurementsHippocampusHuman brainPatientsHydrocortisoneDoseBrainReceptors